Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $42.70.

ARWR has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Wednesday, November 27th. Sanford C. Bernstein lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. Piper Sandler decreased their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Finally, Citigroup dropped their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently made changes to their positions in ARWR. Fifth Third Bancorp raised its position in Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 354 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Meeder Asset Management Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares in the last quarter. Finally, nVerses Capital LLC acquired a new position in Arrowhead Pharmaceuticals during the 2nd quarter worth about $96,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Up 2.4 %

Shares of NASDAQ ARWR opened at $22.37 on Tuesday. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The company has a 50-day moving average price of $21.06 and a 200-day moving average price of $23.14. The stock has a market capitalization of $2.78 billion, a P/E ratio of -4.46 and a beta of 0.91. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $39.83.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.